Dianosic Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Debt
  • (Announced)

  • Investors
  • 15

Dianosic General Information

Description

Developer of long-acting intranasal drug-delivery technology designed to provide targeted and sustained treatment for chronic respiratory and central nervous system diseases. The company's platform combines resorbable polymer inserts, controlled drug release, targeted nasal positioning, and Nose-to-Brain delivery capabilities, enabling pharmaceutical and healthcare partners to develop prolonged treatments for chronic respiratory and central nervous system disorders while reducing the burden of frequent medication.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Place de l'Hôpital
  • Bat PH8
  • 67000 Strasbourg
  • France
+33 01
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Corporate Office
  • 8 Place de l'Hôpital
  • Bat PH8
  • 67000 Strasbourg
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dianosic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Debt - General 02-Jan-2025 Announced Clinical Trials - Phase 1
10. Secondary Transaction - Private Completed Clinical Trials - Phase 1
9. Later Stage VC (Series A) 08-Aug-2025 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A) Cancelled Clinical Trials - Phase 1
7. Later Stage VC 31-Oct-2022 Completed Clinical Trials - Phase 1
6. Equity Crowdfunding 26-Nov-2021 Completed Clinical Trials - Phase 1
5. Early Stage VC 14-Apr-2020 Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 01-Jan-2019 Completed Clinical Trials - Phase 1
3. Angel (individual) 26-Dec-2018 $604K $604K Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 20-Jan-2018 Completed Clinical Trials - Phase 1
To view Dianosic’s complete valuation and funding history, request access »

Dianosic Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Ordinary
Ordinary 4,184 $11.645104 $147.89 $147.89 1x $147.89 8.23%
To view Dianosic’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Dianosic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of long-acting intranasal drug-delivery technology designed to provide targeted and sustained treatment for ch
Drug Delivery
Strasbourg, France
14 As of 2026

Amsterdam, Netherlands
 

Berlin, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dianosic Competitors (6)

One of Dianosic’s 6 competitors is Audion Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Audion Therapeutics Venture Capital-Backed Amsterdam, Netherlands
Biotronik Corporate Backed or Acquired Berlin, Germany
Lyra Therapeutics Formerly VC-backed Watertown, MA
Pfizer (Vienna) Corporation Vienna, Austria
OptiNose Private Equity-Backed PA
To view Dianosic’s complete competitors history, request access »

Dianosic Patents

Dianosic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023303871-A1 Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity Pending 07-Jul-2022
EP-4551201-A1 Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity Pending 07-Jul-2022
US-20250387407-A1 Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity Pending 07-Jul-2022
WO-2024008894-A1 Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity Inactive 07-Jul-2022
FR-3137558-A1 Implant and assembly for medical use for the introduction of such an implant into a cavity of a human or animal body Pending 07-Jul-2022 A61B17/24
To view Dianosic’s complete patent history, request access »

Dianosic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dianosic Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
AptarGroup Corporation Minority
Capital Grand Est PE/Buyout Minority
Finovam Gestion Venture Capital Minority
Noshaq Venture Capital Minority
Afrimobility Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Dianosic FAQs

  • When was Dianosic founded?

    Dianosic was founded in 2017.

  • Where is Dianosic headquartered?

    Dianosic is headquartered in Strasbourg, France.

  • What is the size of Dianosic?

    Dianosic has 14 total employees.

  • What industry is Dianosic in?

    Dianosic’s primary industry is Drug Delivery.

  • Is Dianosic a private or public company?

    Dianosic is a Private company.

  • What is Dianosic’s current revenue?

    The current revenue for Dianosic is .

  • How much funding has Dianosic raised over time?

    Dianosic has raised $15.2M.

  • Who are Dianosic’s investors?

    AptarGroup, Capital Grand Est, Finovam Gestion, Noshaq, and Afrimobility are 5 of 15 investors who have invested in Dianosic.

  • Who are Dianosic’s competitors?

    Audion Therapeutics, Biotronik, Lyra Therapeutics, Pfizer (Vienna), and OptiNose are some of the 6 competitors of Dianosic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process